Healthcare, Pharma & Life Sciences

Scottsdale – – October 14, 2026 -- Senior Helpers has given its highest honor, the Founders Award, to multi-unit franchisees Tiffany and Shaun Phelan, the first couple to receive it, for operating four locations across Arizona and California.

The Phelans own two locations in Scottsdale and Mesa, Arizona, and two in Clovis and Visalia, California. The award goes to owners who champion the brand's programs, support fellow owners and earn the trust of families in their communities. Senior Helpers presented it at its recent annual conference.

Shaun Phelan opened the first Senior Helpers franchise in 2007 and is the longest-tenured owner

Shaun Phelan opened the Scottsdale location in 2007. Tiffany joined the corporate team that same year before opening her first location in the Fresno area. She now leads dementia training for family caregivers and firefighters in California and Arizona. All four locations serve veterans through VA contracts.

Bridgewater, N.J. – – October 14, 2026 -- Insmed (Nasdaq: INSM) will present four abstracts on its investigational inhaled therapy treprostinil palmitil inhalation powder (TPIP) at CHEST 2026 in Phoenix, three of them late-breaking, and two ARIKAYCE abstracts at IDWeek 2026 in Washington, D.C. CHEST runs Oct. 18–21 and IDWeek runs Oct. 21–24.

Chief Medical Officer Martina Flammer said the presentations span the company's respiratory portfolio of BRINSUPRI, TPIP and ARIKAYCE.

Dallas – October 14, 2026 -- Nanoscope Therapeutics has appointed Troy Short, who built the global supply chain for Zolgensma across more than 30 countries at AveXis, as Senior Vice President of Manufacturing and Supply Chain while its lead gene therapy MOGENRY is under regulatory review in the United States and Japan.

Short takes charge of GMP manufacturing, commercial supply and global distribution

Short will lead Nanoscope's GMP manufacturing, commercial supply and global distribution strategy as the company moves toward potential approval and launch of MOGENRY (sonpiretigene isteparvovec; MCO-010). He has more than 20 years of operations and supply chain experience in pharmaceuticals and gene therapy.

His stated priorities are strengthening manufacturing partnerships, building a resilient commercial supply chain and ensuring product availability to patients and physicians upon potential approval.

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

CAPTAIN trial shows whole-gland TULSA cut complication hospitalizations to 0.7% versus 6.3% for robotic surgery

CAPTAIN is the first fully enrolled, multicenter randomized controlled trial to compare the TULSA Procedure directly with robotic radical prostatectomy in localized intermediate-risk prostate cancer. Whole-gland TULSA also showed statistically superior preservation of flaccid penile length at one month.

Indianapolis – October 14, 2026 -- Carnyx Therapeutics Ltd. unveiled CNYX-005, an oral sleep candidate that increased total sleep time by roughly 1.5 to 2 hours in aged rats versus a control arm, as the preclinical-stage company moves toward clinical development.

The increase was driven primarily by more non-rapid eye movement (NREM) sleep. Researchers measured sleep architecture using continuous electroencephalography (EEG) monitoring.

Carnyx hires Chris Brearley, M.D., as Chief Medical Officer ahead of clinical entry

Brearley brings more than 30 years of experience in translational medicine, clinical pharmacology and early-stage drug development. His prior roles include senior positions at Pfizer, Amgen and Serono. He has designed and overseen first-in-human and early-stage clinical studies, the stage CNYX-005 now approaches.

Brearley said he aims to translate the findings into a rigorous clinical development program.

San Diego – – October 14, 2026 -- Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total.

About 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years.

New York – October 14, 2026 -- Consumer365 has recognized Sharps Assure as a notable option for infusion providers researching sharps disposal in 2026, citing its mail-back retrieval systems, five container size tiers and tracking documentation.

Sharps Assure offers containers from compact formats up to 5 gallons

The product range includes compact formats and 1-gallon, 2-gallon, 3-gallon and 5-gallon configurations. Vertical-entry containers are available, as are larger units that accept horizontal or vertical entry. Smaller units may suit individual treatment rooms or low-volume practices, while larger systems may fit facilities that generate sharps throughout the day.

Stockholm – October 14, 2026 -- SciBase Holding AB (STO: SCIB) has received its first positive medical policy for Nevisense from Highmark Blue Cross Blue Shield, which serves more than 7 million members across multiple US states. The decision moves eligible use of the skin-lesion device from a predominantly cash-pay model into covered care through a major private insurer.

Highmark policy applies to all commercial lines and opt-in self-funded groups

Highmark considers electrical impedance spectroscopy (EIS) medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy. The procedure is reported under CPT code 0658T. The policy covers all Highmark commercial insured lines of business and self-funded (ASO) employer groups that elect it.

Coverage is limited to defined cases:

Belfast – October 14, 2026 -- Cumulus Neuroscience and Transpharmation Ltd. have formed a strategic partnership to align EEG and behavioral endpoints from preclinical models through first-in-human trials, targeting a therapeutic area where an estimated 6.7% of candidates progress from nonclinical development to FDA approval (Sertkaya et al., JAMA Netw Open, 2024).

Partners target the measurement break between animal studies and Phase 1

The two companies will jointly advise biopharma sponsors preparing for first-in-human studies. They will recommend which EEG paradigms to run preclinically based on how the same measures will be captured in the clinic. Each company will no longer scope its portion of a programme in isolation.

Maastricht – October 14, 2026 -- More than half of respondents to the MAPPA patient survey received a primary immunodeficiency (PID) diagnosis after age 18, and 28% reported permanent damage at the time of diagnosis, according to preliminary findings Kedrion Biopharma and AIP APS will present at ESID 2026.

MAPPA survey expands from Italy to Portugal, Spain and Turkey

The survey was developed by AIP APS, the Italian Association for Primary Immunodeficiencies, in collaboration with Kedrion. It collects real-world data on the experiences of people living with PIDs across Europe. The expansion from Italy to Portugal, Spain and Turkey is expected to provide new evidence on patient pathways, diagnostic journeys and unmet needs.

AIP APS President Alessandro Segato said that turning patient experiences into evidence helps identify shared needs that might otherwise remain unseen, and can strengthen diagnosis, care and support at a European level.